Experiments were conducted to elucidate that SIN inhibits tumor-derived DNA tumor-induced HCC cells and induces cell proliferation through CXCL12-CXCR4 and CCL21-CCR7 axis signaling pathways, aiming to provide possible drug selection and relevant preclinical evidence for clinical HCC treatment. This evidence concerns the gene CXCR4 and neoplasm.